CrunchBase is hiring! Check out our open positions →
Register | Login or Login

Exit

PublicNASDAQ: OREX
Date7/07
Raised
Post IPO Valuation

General Information

Websiteorexigen.com
CategoryBioTech
Phone(858) 875-8600
Emailinfo@orexigen.com
Employees
Founded2002

Offices

La Jolla, USA
3344 N. Torrey Pines Court
Suite 200
La Jolla, CA, 92037
USA

People

boards of directors
Director

Former People

Investor

Tags

Orexigen Therapeutics

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its lead combination product candidates include Contrave, which has completed Phase III clinical trials; and Empatic that has completed Phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release formulation (SR). Bupropion is an antidepressant and smoking cessation medication; naltrexone is a treatment for alcohol and opioid addiction. The company’s Empatic product candidate is a combination of bupropion SR and zonisamide SR. Zonisamide, in an immediate release formulation for the adjunctive treatment of partial seizures, a form of epilepsy. The company was founded in 2002 and is based in La Jolla, California.

Recent Milestones

Videos

Screenshots

Orexigen Therapeutics screenshot
Above: Home Page
Uploaded: 5/31/10

Stock Price

Sources

Edit This Page
Last Edited 5/2/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy